๐ฌ Lung/Head and Neck/Thymoma Intelligence Digest โ Week 2026-W43
This week: AMAZE-Lung triplet after 3G EGFR-TKI progression, FURTHER firmonertinib in PACC mutations, RET-MAP real-world post-RET-inhibitor outcomes, BNT113's negative PFS in HPV16+ HNSCC, MAVERICK and radiosurgery reshaping brain-directed therapy in SCLC, and a Pan-Asian ESMO guideline adaptation for early NSCLC.
โก TL;DR
๐ Publications
- Firmonertinib in advanced non-small cell lung cancer with epidermal growth factor receptor P-loop and ฮฑC-helix compressing mutations. โ Phase 1b FURTHER randomized patients with metastatic EGFR PACC-mutant NSCLC to first-line firmonertinib 160 mg (n=25) or 240 mg (n=22)
๐ฆ Twitter / ๐ฆ Bluesky
- Cancer plasticity and histological transformation reviewed in Med as an adaptive resistance mechanism across precision oncology โ The review examines histological transformation as an escape route in which a cancer responding to targeted therapy changes its identity, from adenocarcinoma to small cell or squamous
- Perioperative therapy in oncogene-driven NSCLC: targeted therapy in resectable disease and the unanswered neoadjuvant-versus-adjuvant question โ An ASCO Educational Book article addresses perioperative therapy in oncogene-driven NSCLC, current strategies and unanswered questions
- Health-system-scale cachexia atlas in Nature Medicine builds prospective risk models for lung cancer โ A health-system-scale cachexia atlas of 52K patients describes and predicts outcomes, with prospective risk models for lung, colorectal, and prostate cancer
- AMAZE-Lung publishes in Lancet Respiratory Medicine: amivantamab-lazertinib-bevacizumab meets its 12-week ORR bar after 3G EGFR-TKI progression, with heavy toxicity โ International single-arm phase II in 61 patients, 30% with baseline brain metastases, median follow-up 9.0 months
- Update: MAVERICK and NRG-CC009 together are being presented as having fundamentally changed brain-directed therapy in SCLC โ SWOG S1827 (MAVERICK) randomized 304 patients, 68% limited-stage, to MRI surveillance alone versus MRI plus PCI 25 Gy/10 fx, with cognitive failure-free survival HR 0.60 (90% CI 0.46-0.78)
Full details below โ
๐ What's Being Published
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with early and locally advanced non-small-cell lung cancer. โ Hayashi H et al., ESMO Open
The ESMO guidelines for early and locally advanced NSCLC, published in August 2025, were adapted in November 2025 into Pan-Asian consensus guidelines by a panel representing the oncological societies of ten Asian countries, coordinated by ESMO and JSMO. Voting was based on scientific evidence and was independent of current treatment practices, drug access restrictions and reimbursement decisions across Asia. The document explicitly flags disparity in drug approvals and reimbursement among Asian regions.
Clinical bottom line: For clinicians practising in Asia, this adaptation aligns early and locally advanced NSCLC management with ESMO recommendations and separates what is evidence-based from what is locally reimbursable.
Firmonertinib in advanced non-small cell lung cancer with epidermal growth factor receptor P-loop and ฮฑC-helix compressing mutations. โ Le Xiuning et al., Cancer Cell
In the phase 1b FURTHER study, patients with metastatic EGFR PACC-mutant NSCLC were randomized to first-line firmonertinib 160 mg (n = 25) or 240 mg (n = 22). Confirmed ORRs were 43% and 68%, median PFS 11.1 and 16.0 months, and median DoR not reached and 14.6 months, respectively. Intracranial ORR in patients with baseline brain metastases was 47% (8/17). Treatment-related adverse events led to dose reductions in 19% and 24% and to discontinuation in 3% and 0%.
Clinical bottom line: Firmonertinib 240 mg gives the strongest first-line activity reported so far in EGFR PACC-mutant NSCLC, including intracranially, and should be pursued in trials rather than assumed equivalent to standard third-generation TKIs.
Validation of Immunoscore for Prognostic Stratification in HPV-associated Oropharyngeal Cancer: An International Multicenter Study. โ Nguyen Dac Hung et al., Clin Cancer Res
The study analyzed 191 HPV-associated OPSCC patients, with a training cohort (n = 48) and three validation cohorts (n = 48, n = 50, n = 45). On multivariable analysis, IS-Low was the independent prognostic factor with the largest adjusted effect size for DFS (HR 9.03; 95% CI: 4.02-20.31; P < .001). The combined IS-clinical model outperformed the clinical-only model (C-index 0.82 vs 0.70; P < .0001), and IS-High patients had superior 3-year DFS across cohorts (all log-rank P < .05).
Clinical bottom line: Immunoscore outperformed TNM and smoking-based stratification for DFS in HPV-associated oropharyngeal cancer. It is the most credible candidate yet for selecting patients for de-escalation trials, but it is not ready for routine use outside them.
Second- and third-line outcomes after selective RET inhibitor failure in RET fusion-positive metastatic lung cancer: A real-world analysis from the RET-MAP registry. โ Miliziano Daniela et al., Clin Cancer Res
Of 207 patients treated with a first-line selective RET inhibitor, 81 (39%) discontinued for progression and 65 (80%) received subsequent therapy, most commonly platinum-pemetrexed with or without immunotherapy (n=35, 54%). At 53 months' median follow-up, second-line real-world ORR was 41% (12/29), median rwPFS 6.1 months (95% CI 4.8-11.4) and median OS 13.7 months (95% CI 8.7-26.5). Chemotherapy alone and chemo-immunotherapy gave similar rwPFS (5.9 vs 6.8 months; HR 1.05, p=0.903) and OS (18.5 vs 13.7 months; HR 0.83, p=0.674). Third-line taxane with or without antiangiogenic therapy (n=11) produced no responses and a median rwPFS of 1.5 months (95% CI 0.8-NR).
Clinical bottom line: After progression on a selective RET inhibitor, platinum-pemetrexed is the defensible second-line choice, adding immunotherapy offers no benefit, and third-line taxanes are essentially inactive. These figures are now the benchmark that single-arm trials must beat.
Lazertinib plus pemetrexed and carboplatin in patients with EGFR-mutant advanced non-small cell lung cancer after progression on lazertinib. โ Hong Min Hee et al., Eur J Cancer
The single-arm phase II LUCAS trial enrolled 86 patients, 46.5% with a history of brain metastases. Median PFS was 9.5 months (95% CI: 6.3-9.6; one-sided p = 0.017 against a null median of 6.0 months), median OS was 15.9 months (95% CI: 12.4-20.0) and ORR was 36.0% (95% CI: 26.0-47.1). Among 36 patients with radiologically evident baseline brain metastases, median intracranial PFS was 9.9 months (95% CI: 7.8-16.4). Grade โฅ3 adverse events occurred in 69.8%, predominantly hematologic.
Clinical bottom line: Continuing lazertinib with platinum-pemetrexed after lazertinib progression meets its PFS bar with good intracranial control. Without a randomized comparison, however, it does not justify abandoning chemotherapy alone as the standard next line.
Cobimetinib + Vemurafenib in Patients With BRAF V600E-Mutant Papillary Thyroid and Biliary Tract Cancers: Results From the TAPUR Study. โ Diamond-Rossi Samantha A et al., JCO Precis Oncol
TAPUR enrolled BRAF V600E-mutant thyroid cancer (N = 22; n = 16 evaluable) and biliary tract cancer (N = 18; n = 15 evaluable) patients. In the thyroid cohort, disease control was 94% (one-sided 90% CI, 78 to 100) and objective response 63% (95% CI, 35 to 85). The null hypothesis of a 15% disease control rate was rejected for both cohorts (P < .0001). Twenty-one patients (53%) had at least one treatment-related grade 3 to 4 or serious adverse event.
Clinical bottom line: Cobimetinib plus vemurafenib is an active off-label option for BRAF V600E-mutant papillary thyroid cancer when no standard options remain, but the 53% rate of grade 3-4 or serious toxicity makes it far from a benign choice.
๐ Every paper considered this week, including the ones that didnโt make it โ
๐ฃ๏ธ What People Were Discussing This Week
How these are chosen: filtered for clinical relevance, grouped by the new development discussed, then ordered by engagement (bookmarks and reposts).
Cancer plasticity and histological transformation reviewed in Med as an adaptive resistance mechanism across precision oncology
A narrative review in Med examines histological transformation as a resistance mechanism in which a cancer responding to targeted therapy changes identity, for example from adenocarcinoma to small cell or squamous. It is a review with no new outcome data. Its motivating cases are anecdotal: NSCLC adenocarcinoma becoming small cell lung cancer after a RET inhibitor, papillary thyroid cancer turning anaplastic after a BRAF inhibitor, and glioblastoma transforming to gliosarcoma after BRAF/MEK inhibition. At DCLung26, clinicians emphasized repeat biopsy to rule out small cell transformation and repeat NGS at relapse. This raises the question of whether re-biopsy should be mandatory at every progression on a targeted agent in lung and thyroid cancer, rather than reserved for atypical courses.
Discussed by: @VivekSubbiah, @jillfeldman4, @NaglaAKarimMD
Sources cited: Cell Press
Perioperative therapy in oncogene-driven NSCLC: targeted therapy in resectable disease and the unanswered neoadjuvant-versus-adjuvant question
An ASCO Educational Book article on perioperative therapy in oncogene-driven NSCLC cites approvals in EGFR, ALK and RET, with other targets in development. Clinicians stressed the need for comprehensive biomarker testing at all stages before treatment decisions. Two questions remain open: whether neoadjuvant targeted therapy adds anything to adjuvant therapy, and whether more patients are being cured or micrometastases are simply being treated earlier, given the unknown risk of stopping adjuvant therapy.
Discussed by: @n8pennell, @NarjustFlorezMD, @jillfeldman4
Sources cited: Perioperative Therapy in Oncogene-Driven NonโSmall Cell Lung Cancer: Current Strategies aโฆ (American Society of Clinical Oncology Educational Book, 2025)
Health-system-scale cachexia atlas in Nature Medicine builds prospective risk models for lung cancer
A health-system-scale cachexia atlas in Nature Medicine (52K patients) describes and predicts outcomes, with prospective risk models for lung, colorectal and prostate cancer. Separately, in head and neck cancer patients receiving radiotherapy, higher skeletal muscle and lower intermuscular adiposity on pretreatment CT were associated with improved overall survival. The open question is whether these models are mature enough to trigger nutritional or pharmacologic intervention at diagnosis, or whether they remain prognostic description.
Discussed by: @EladSharonMD, @JAMAOto
Sources cited: A health-system-scale, episode-resolved multimodal atlas of cancer cachexia (Nature Medicine, 2026) ยท JAMA Network
AMAZE-Lung publishes in Lancet Respiratory Medicine: amivantamab-lazertinib-bevacizumab meets its 12-week ORR bar after 3G EGFR-TKI progression, with heavy toxicity
ETOP 18-21 AMAZE-Lung is described as the first prospective trial of a triplet biologic combination targeting EGFR, MET and VEGF in acquired resistance to third-generation EGFR TKIs. This international single-arm phase II met its prespecified 12-week response threshold, with no treatment-related deaths. Toxicity was heavy, with frequent infusion reactions, acneiform rash and venous thromboembolism. Clinicians debate whether that response rate justifies the triplet's toxicity after osimertinib progression, or whether chemotherapy-based regimens should remain the default second line.
Key numbers: 12-week ORR 33% (20/60) ยท Overall PR 39% (24/61) ยท โฅG3 TRAEs 43% ยท IRR 58% ยท VTE 17% (grade 3โ4: 3%)
Discussed by: @DrSanjayPopat, @ManuelDomine
Sources cited: Combined amivantamab, lazertinib, and bevacizumab in patients with EGFR-mutant advanced nโฆ (The Lancet Respiratory Medicine, 2026)
Update: MAVERICK and NRG-CC009 together are being presented as having fundamentally changed brain-directed therapy in SCLC
In SWOG S1827 (MAVERICK), MRI surveillance alone improved cognitive failure-free survival over MRI plus PCI and caused fewer severe treatment-related events. Preliminary overall survival was not significantly different, with the final analysis pending, and these are meeting data not yet peer-reviewed. At ASTRO, the first randomized phase 3 comparison linked radiosurgery to longer survival for SCLC brain metastases, challenging reliance on whole brain treatment; radiation oncologists say the approach has fundamentally changed. Open issues remain: whether services can deliver a 3-month MRI schedule, whether the non-significant survival result leaves room for PCI in selected limited-stage patients, and the resected setting pending PRIMALUNG.
Key numbers: CFFS HR 0.60 (90% CI 0.46โ0.78) ยท Grade 3โ5 TRAEs 0.8% vs 7.9% ยท OS HR 0.90 (90% CI 0.67โ1.20), preliminary
Discussed by: @drgandara, @lauren_henke, @tnewsomdavis, @DrRiyazShah
Prospective cardiac monitoring finds lung SBRT safe for tumors within 3 cm of the heart, while surgical approach in stage I NSCLC stays unsettled
A prospective cardiac monitoring study from the AUMC group provides reassuring evidence on lung SBRT for tumors within 3 cm of the heart. It suggests earlier estimates of increased cardiac risk were confounded by pre-existing cardiopulmonary comorbidities. A 2025 ASTRO presentation of SABR versus VATS showed no inferiority in overall survival at 10 years, though the manuscript is not yet published. The phase III VALOR trial is testing upfront surgery against upfront SBRT, and it remains unknown whether surgical incisions propagate metastatic progression. The open question is whether operable stage I patients should be offered SBRT as a genuine alternative before VALOR reports.
Discussed by: @DrewMoghanaki, @JoeChangMD
Sources cited: ScienceDirect
ASCO opens draft guideline recommendations for stages I-III NSCLC to public comment while the living guideline for stage IV driver alterations updates
ASCO's draft recommendations for Management of Stages I-III Non-Small Cell Lung Cancer are open for public comment until October 26. ASCO also published Version 2026.3.3 of its living guideline for stage IV NSCLC with driver alterations. A Radium Society Appropriate Use Criteria for accelerated hypofractionated radiation in locally advanced NSCLC is in press at IJROBP. Clinicians are asking which unresolved stage I-III questions, such as perioperative versus adjuvant targeted therapy or who actually reaches surgery, the draft must address before comments close.
Discussed by: @RManochakian, @jryckman3
Sources cited: Therapy for Stage IV NonโSmall Cell Lung Cancer With Driver Alterations: ASCO Living Guidโฆ (Journal of Clinical Oncology, 2026)
DECIDE-MET (JCOG2506) launches a randomized phase III of MET TKI versus pembrolizumab-based therapy in first-line METex14 NSCLC
DECIDE-MET (JCOG2506) randomizes first-line METex14 NSCLC to capmatinib/tepotinib versus pembrolizumab (PD-L1 โฅ50%) or pembrolizumab plus platinum chemotherapy (<50%). Unlike other actionable alterations, METex14 can respond to checkpoint inhibitors, especially with PD-L1 above 80% and a smoking history; one teaching point holds that first-line ICI with or without chemotherapy may outperform a MET TKI in that group. Capmatinib and tepotinib remain preferred. METex14 occurs across histologies, and RNAseq can find cases that DNAseq misses. The debate is whether high PD-L1 with a smoking history should already push patients toward checkpoint inhibition before the trial reads out.
Discussed by: @TejasPatilMD, @StephenVLiu, @StephenVLiu
FURTHER phase 1b: first-line firmonertinib produces a 68% response rate at 240 mg in EGFR PACC-mutant NSCLC
PACC mutations are a structurally distinct EGFR subgroup with limited treatment options. In FURTHER, the higher firmonertinib dose produced both more responses and longer progression-free survival than the lower dose, with intracranial activity in evaluable brain metastases. Dose reductions were more frequent at the higher dose. The open question is whether 240 mg should be used off-trial, or whether a randomized comparison against osimertinib is needed first.
Key numbers: ORR 68% vs 43% (240 vs 160 mg) ยท Median PFS 16 vs 11.1 mo ยท Intracranial response 47% ยท Dose reductions 19% and 24%
Discussed by: @ilyassahinMD, @jillfeldman4
LIGHT-NING real-world Japanese data put numbers on nivolumab plus ipilimumab with and without chemotherapy in NSCLC
Real-world LIGHT-NING data show modestly longer survival when chemotherapy is added to nivolumab plus ipilimumab, at the cost of substantially more severe treatment-related toxicity. Clinicians are asking which NSCLC patients still warrant chemotherapy alongside dual checkpoint blockade given that trade-off.
Key numbers: OS 21.7 vs 18.8 mo (with vs without chemo) ยท PFS 6.8 vs 6.3 mo ยท G3+ TRAEs 53% vs 31%
Discussed by: @StephenVLiu, @phsiao4
Sources cited: Lung Cancer
EMERGE-402 real-world lurbinectedin in relapsed SCLC: 29% response and 7.6-month OS, split by platinum sensitivity
EMERGE-402 real-world data on lurbinectedin in relapsed SCLC show survival differing by platinum sensitivity, with low discontinuation for adverse events. With tarlatamab established in second line and B7-H3 ADCs reporting survival gains, clinicians are asking where lurbinectedin now sits in the relapsed sequence.
Key numbers: RR 29% (33% as 2L) ยท PFS 3.3m ยท OS 7.6m ยท OS 5.8m resistant vs 9.3m sensitive ยท AE discontinuation 8%
Discussed by: @StephenVLiu, @phsiao4
Sources cited: Lung Cancer
Savolitinib plus osimertinib NDA filed with the FDA for MET-driven, EGFR-mutated NSCLC after EGFR TKI
An NDA for savolitinib plus osimertinib in MET-driven, EGFR-mutated NSCLC after EGFR TKI has been submitted to the FDA, supported by phase 3 data. Clinicians note that resistance patterns such as MET amplification shift post-osimertinib plans, and at DCLung26 they emphasized repeat biopsy and molecular testing at resistance. The question is whether approval would make repeat tissue biopsy at progression mandatory rather than optional.
Discussed by: @NaglaAKarimMD, @HosseinBorghaei
AHEAD-MERIT: BioNTech's HPV16 mRNA immunotherapy BNT113 plus pembrolizumab fails PFS in first-line recurrent/metastatic HNSCC
BNT113 (tenumomeran/raplemomeran) plus pembrolizumab did not significantly improve PFS over pembrolizumab alone in first-line unresectable recurrent or metastatic HPV16+ HNSCC expressing PD-L1. The randomized portion of the phase 2/3 AHEAD-MERIT trial continues to assess the co-primary endpoint of overall survival. Clinicians debate whether that is a legitimate second chance for an HPV16 vaccine or an attempt to rescue a failed trial.
Discussed by: @PaulJiL, @MorningGlorySci
Sources cited: Cancer Network ยท OncLive
Pooled analysis of 24 ADC trials in lung cancer quantifies pulmonary toxicity across 2,855 patients
A meta-analysis of ADC-treated SCLC and NSCLC patients quantified pulmonary adverse events, pneumonitis/ILD and pulmonary-related mortality across trials. A separate T-DXd dataset showed higher ILD/pneumonitis rates, including fatal cases. Clinicians are asking how this pulmonary risk should be weighed when choosing between a HER2 TKI and an ADC in the frontline setting.
Key numbers: Any-grade pulmonary AEs 30.9% ยท Gr โฅ3 6.9% ยท Pneumonitis or ILD 8.0% ยท Pulmonary AE-related mortality 1.96%
Discussed by: @ChristianRolfo, @phsiao4
ESMO26 abstracts drop: a meta-analysis finds BRAF/MEK inhibitors beat immunotherapy on response but not survival in BRAF V600E NSCLC
Among 589 patients with BRAF V600E NSCLC, BRAF/MEK inhibitors achieved higher response rates than ICI-based regimens, 61% versus 48%, with no differences in PFS or OS. Discussants argue immunotherapy still plays a large role even with an actionable mutation, and one prefers encorafenib plus binimetinib when using BRAF/MEK inhibition. The debate is which agent should go first, and whether that changes with high PD-L1.
Discussed by: @dr_yakupergun, @OncBrothers
๐ฅ Top Ranked Tweets
Dra. Marรญa Natalia Gandur Quiroga @nataliagandur
RT @OncoAlert: Is topotecan finished in relapsed SCLC? ๐ซ
Two phase 3 trials of B7-H3 ADCs both beat it:
๐น Tam-Peli (NEJM): OS 13.3 vs 9.4 mo, HR 0.46. ORR 59% vs 10%.
https://t.co/pO4dceeRCb
๐น Ris-Rez (ARTEMIS-008, #WCLC26): OS 18.5 vs 10.3 mo, HR 0.46. ORR 58% vs 13%.
Both also had fewer grade โฅ3 AEs than topotecan.
https://t.co/uQ8s7VcwXB
๐ฅ Dr. @UOzkerim& Dr. Aslฤฑ Geรงgel from Istanbul ๐น๐ท break down what this means for practice.
#LCSM #SCLC #LungCancer
@peters_solange, @christine_lovly, @GlopesMd, @DrSanjayPopat, @StephenVLiu, @HenningWillers, @HHorinouchi, @BRicciutiMD, @PercyLeeMD, @jillfeldman4, @bensolomon1, @Latinamd, @DrJNaidoo, @barlesi, @UOzkerim, @FernandoOnco, @DrMirallas, @VanitaNoronha, @NarjustFlorezMD, @MartinReck2, @realbowtiedoc, @ElisaAgostinett, @to_be_elizabeth, @MarioBalsaMD, @p_ciracimd, @AmandaNizamMD, @scocmem, @DrVilmaPBarcia, @DraMartinezLago, @nataliagandur, @GIMedOnc, @DaisukeKotani
๐ 5 โค๏ธ 23 ๐ 14 ๐ 2,694
Journal of Clinical Oncology @JCO_ASCO
Therapy for Stage IV NonโSmall Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2026.3.3.
Read the full article. https://t.co/4fLMu8TkZQ
#NSCLC
๐ 1 โค๏ธ 9 ๐ 3 ๐ 1,861
David Gandara @drgandara
RT @oncologytube: VIDEO: MRI surveillance alone in SCLC โ skip PCI? MAVERICK 2026: cognitive failure-free survival HR 0.60 ๐ง ๐ซ
๐ https://t.co/0pvZilOEC0
๐น SWOG S1827 phase 3 (N=304; 68% limited-stage): MRI alone vs MRI + PCI (25 Gy/10 fx)
๐น CFFS HR 0.60 (90% CI 0.46โ0.78); grade 3โ5 TRAEs 0.8% vs 7.9%
๐น OS preliminary: HR 0.90 (90% CI 0.67โ1.20) at 128 of 190 deaths; final analysis pending
Meeting data, not yet peer-reviewed. Can your patient keep a 3-month MRI schedule?
@PDBrownOnc @StephenVLiu @TejasPatilMD @drshieldsmd @KatieKeaneMD @HenningWillers @DrewMoghanaki @bslotman @aadel_chaudhuri @HenryParkMD @StephenChunMD @lauren_henke @JeffBradleyMD @CJTsaiMDPhD @MichelleMKimMD @MartinTomMD @NarjustFlorezMD @HosseinBorghaei @marinagarassino @drgandara @RielyMD @TommyJohn00 @DevikaDasMD @Latinamd @GlopesMd @tnewsomdavis @M_Torasawa @TugceKutukMD @DMoorePalhares @ChrisFloresRT @barrosonco @RobertoBoreaMD @TomVargheseJr @dr_yakupergun @ChandrakanthMv
#SCLC #lcsm #MAVERICK #PCI #radonc #btsm
๐ 2 โค๏ธ 10 ๐ 3 ๐ 972
IASLC @IASLC
Adjuvant osimertinib demonstrates sustained OS benefit in resected EGFR-mutated NSCLC, according to data presented at #WCLC26 by @DrRoyHerbst
๐ Read highlights from the global phase III ADAURA trial now in ILCN: https://t.co/tLeKhSEsRg
#LCSM
๐ 0 โค๏ธ 13 ๐ 2 ๐ 767
Yakup Ergรผn @dr_yakupergun
The FDA approved 22 new drugs in Q3 2026.
Key oncology approvals:
- Daraxonrasib
- Gedatolisib
- Camizestrant
- Zidesamtinib
- Lirafugratinib
Daraxonrasib leads commercial forecasts, with projected annual sales of $6.6 billion by 2032.
https://t.co/uuiNqvEAyW https://t.co/894kkVEIf6
๐ 37 โค๏ธ 71 ๐ 21 ๐ 4,914
Katsuaki Maehara ๐ฏ๐ต @KatsuakiMaehara
๐ซ๐ซ EGFR Ex20ins ๐ซ๐ซ
๐ฅ Clinical trial data updated from #WCLC26 https://t.co/GThXXqWgXJ
๐ 31 โค๏ธ 44 ๐ 10 ๐ 3,199
Sanjay Popat @DrSanjayPopat
RT @M_Torasawa: AMAZE-Lung:ย
Amivantamab + Lazertinib + Bevacizumab following progression on 3G EGFR-TKIs.
๐ Lancet Respir Med 2026
https://t.co/67Y4Y3DUvJ
๐ International, single-arm Phase II trial (N=61)
๐ง Baseline brain metastases: 30%
โณ Median follow-up: 9.0 months
๐ฏ 12-week ORR (primary endpoint): 33% (20/60) โ met the prespecified threshold
๐ Overall partial response: 39% (24/61)
โ ๏ธ Safety
โฅG3 TRAEs: 43%
IRR: 58%
Acneiform rash: 50%
VTE: 17% (grade 3โ4: 3%)
No treatment-related deaths
๐ 24 โค๏ธ 45 ๐ 10 ๐ 5,139
Yago Garitaonaindรญa @YGaritaonaindia
RT @KRASKickers: KRAS G12D specific trials
Found nine Phase 1 and
twenty-two Phase 2 or 3 trials
Using the Evolving chart of RAS Inhibitors in Development to track the G12D trial options -
"A continuously updated map of every RAS inhibitor & degrader in clinical development โ 75 drugs, from Phase 1 to FDA approval. The entire clinical RAS pipeline at a glance, updated regularly. "
https://t.co/89MsT8chBD
https://t.co/eK7zB4qZd2
Phase 1 trials - nine results
QTX3034 OR QLC1101 OR PT0253 OR LY3962673 OR BAY 3771249 OR HBW-012336 OR GDC-7035 OR D35-003
Search: https://t.co/wcYEf3fVDe
Phase 2 and 3 - trials - 22 trial results
TSN1611 OR Zoldonrasib OR VS-7375 OR Setidegrasib OR INCB161734 OR RMC-9805 OR ASP3082
https://t.co/ulm8KiPP5q
NOTE: I left off the trials ONLY available in China
You can edit the search for your country, tumor type (some of the Phase 3 trials are ONLY for Pancreatic Cancer). BUT a lot of trials are for "SOLID TUMORS" so also relevant to other cancer types.
And there is a "MAP" where you can see the trials in Canada, Europe, Asia, Australia
๐ 22 โค๏ธ 46 ๐ 16 ๐ 2,683
MV Chandrakanth @ChandrakanthMv
๐ THE PACIFIC PPI PARADOX
Is the PPI Really Guilty?
Do PPIs reduce durvalumab efficacy, or are we blaming the wrong culprit?
Part 1 โ The PACIFIC Puzzle
Poorer survival associated with PPI use on durvalumab, but not placebo. Why?
Part 2 โ The Hidden Confounder
5,742 patients. Among ICI-treated patients:
โข Non-prophylactic PPI: HR 1.22
โข Prophylactic PPI: HR 0.93
Same drug. Different indications. Different associations.
Part 3 โ The Clinical Verdict
Drug effect or underlying patient biology? Should we stop PPIs?
๐ก TAKE-HOME
Association โ Causation.
Avoid unnecessary PPIs, but don't routinely stop clinically indicated PPIs.
Before blaming the PPI, ask why it was prescribed.
๐ References
Brunetti et al. Lancet Oncol. 2026;27:1043โ56.
Metselaar-Albers et al. Lancet Oncol. 2026;27:e446.
#PACIFIC #Durvalumab #NSCLC #Immunotherapy #LungCancer #EvidenceBasedOncology
๐ 15 โค๏ธ 28 ๐ 8 ๐ 1,951
Nathan A. Pennell MD, PhD, FASCO @n8pennell
Perioperative Therapy in Oncogene-Driven NonโSmall Cell Lung Cancer: Current Strategies and Unanswered Questions | American Society of Clinical Oncology Educational Book https://t.co/OiPeK0Uxu1 #ASCO25 #EdBook https://t.co/NICk9LCGmz
๐ 14 โค๏ธ 49 ๐ 18 ๐ 5,864
Masahiro TORASAWA, MD. PhD. @M_Torasawa
๐ฏ๐ต JCOG2510 (PRIME-CRT)
Phase III
โข๏ธ Can induction Chemo-IO improve survival in unresectable locally advanced NSCLC?
๐ต cCRT โ Durvalumab
vs.
๐ด Chemo + Pembrolizumab (2 cycles) โ cCRT โ Durvalumab
๐ฏ N=212 | Primary endpoints: PFS & OS
๐ https://t.co/KPeTX6Q3Mo
@masuken04127
@JCOG_official
๐ 14 โค๏ธ 38 ๐ 4 ๐ 3,373
OncoAlert @OncoAlert
RT @DrRishabhOnco: ๐จ 19.3-MONTH PFS IN ADVANCED THYMIC CANCER!
Toripalimab + Carboplatin/Paclitaxel | Phase II | ESMO Open 2026
๐ Key Results (N=24)
โข Median PFS: 19.3 months
โข ORR: 37.5%
โข Disease control: 100%
โข Median DoR: 26.4 months
โข Grade 3โ4 TRAEs: 50%
โข Myocarditis: 8.3%
๐งฌ Biomarker signal: NF-ฮบB pathway mutations associated with longer PFS (30.7 vs 14.2 months; HR 0.21).
๐ก Verdict: Promising efficacy, but caution! Single-arm study, small sample, and clinically important immune toxicity. Randomized validation needed.
@ASCO @OncoAlert
#ThymicCancer #Immunotherapy #Oncology
๐ 11 โค๏ธ 36 ๐ 13 ๐ 2,278
Balazs Halmos @BalazsHalmosMD
RT @StephenVLiu: Real world outcomes with lurbinectedin in SCLC from EMERGE 402 study by @BalazsHalmosMD in Lung Cancer. In 267 pts, RR 29% (33% as 2L) with PFS 3.3m, OS 7.6m (5.8m for platinum resistant, 9.3m for sensitive). 8% discontinuation rate due to adverse event.
https://t.co/rOPEzYhQsQ
๐ 9 โค๏ธ 39 ๐ 8 ๐ 2,794
Stephen V Liu, MD @StephenVLiu
Real world outcomes with lurbinectedin in SCLC from EMERGE 402 study by @BalazsHalmosMD in Lung Cancer. In 267 pts, RR 29% (33% as 2L) with PFS 3.3m, OS 7.6m (5.8m for platinum resistant, 9.3m for sensitive). 8% discontinuation rate due to adverse event.
https://t.co/rOPEzYhQsQ
๐ 9 โค๏ธ 39 ๐ 8 ๐ 2,794
Tejas Patil @TejasPatilMD
RT @StephenVLiu: Real world outcomes with lurbinectedin in SCLC from EMERGE 402 study by @BalazsHalmosMD in Lung Cancer. In 267 pts, RR 29% (33% as 2L) with PFS 3.3m, OS 7.6m (5.8m for platinum resistant, 9.3m for sensitive). 8% discontinuation rate due to adverse event.
https://t.co/rOPEzYhQsQ
๐ 9 โค๏ธ 39 ๐ 8 ๐ 2,795
๐งช Newly Recruiting Trials
8 trials (1 phase III, 6 phase II, 1 phase I) opened this week, testing zipalertinib, alirocumab, SX-682, ivonescimab and sacituzumab govitecan, stereotactic body radiation therapy, cyclosporine A, obrixtamig plus pumitamig and ABBV-253
Phase 3 ยท Taiho Oncology, Inc. ยท zipalertinib ยท Alaska, California, District of Columbia, Florida, Georgia, Illinois +7 more ยท CT.gov โ
Phase 2 ยท Duke University ยท alirocumab ยท North Carolina ยท CT.gov โ
Phase 1/2 ยท National Cancer Institute (NCI) ยท SX-682 ยท Maryland ยท CT.gov โ
Phase 2 ยท SWOG Cancer Research Network ยท ivonescimab and sacituzumab govitecan ยท California, Georgia, Idaho, Illinois, Michigan, Missouri +5 more ยท CT.gov โ
Phase 2 ยท Mark Bernard ยท stereotactic body radiation therapy ยท Kentucky ยท CT.gov โ
Phase 2 ยท NYU Langone Health ยท cyclosporine A ยท New York ยท CT.gov โ
Phase 1/2 ยท Boehringer Ingelheim ยท obrixtamig plus pumitamig ยท Florida, Massachusetts, New Jersey, New York, Tennessee ยท CT.gov โ
Phase 1 ยท AbbVie ยท ABBV-253 ยท Michigan, North Carolina, Texas ยท CT.gov โ
Open all 8 on the trials page โ
Agent descriptions from the NCI Thesaurus.
Prepared by Rafael Santana-Davila, M.D. Questions or feedback? Just reply to this email.
Disclaimer: This digest is AI-generated. Content may contain errors -- always verify with original sources.
Know a colleague who would find this useful? Just forward them this email.
☕ Not funded by anyone — no sponsors, no pharma. Buy me a coffee if it's useful.